The biotech industry is constantly evolving with new developments in medications and treatments. Novo Nordisk’s Ozempic has shown benefits beyond diabetes, while Alnylam Pharmaceuticals’ zilebesiran has shown promise in lowering blood pressure. However, biotech VC funding is shrinking, with fewer deals and less money being raised. Apogee Therapeutics’ antibody treatment has shown positive results, and BridgeBio Pharma’s recent deal has caused some stock volatility. Meanwhile, the approval timeline for Eli Lilly’s Alzheimer’s treatment is uncertain. The industry is also facing challenges with the FDA and manufacturing issues. Stay informed with a biotech newsletter for more updates.
Source link
The latest on Novo Nordisk, Alnylam, Apogee
